Recent Updates
Recently added Catalysts
TVTX Positive Sentiment

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Friday, October 2, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Travere Therapeutics announced it will present nine new data presentations at ASN Kidney Week 2026, including five oral presentations. The data focuses on the efficacy of FILSPARI® (sparsentan) in treating patients with IgA nephropathy and focal segmental glomerulosclerosis. The final SPARTAN analysis is expected to provide significant insights into the treatment's potential.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data presentations highlight efficacy of FILSPARI®.
  • Five oral presentations indicate strong research support.
  • Focus on IgA nephropathy and FSGS shows targeted treatment approach.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+68%
120-day peak, hindsight
Typical move
8.6%
average across 10 past catalysts
Lead asset
Sparsentan
Phase 2 · ANCA Associated Vasculitis

Full Press Release Details

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)."The final SPARTAN analysis provides a compelling picture of what's possible whe

Frequently Asked Questions

What will Travere present at ASN Kidney Week 2026?

Travere will present nine new data presentations, including five oral presentations.

What is FILSPARI® used for?

FILSPARI® (sparsentan) is being studied for its effectiveness in treating IgA nephropathy and FSGS.

Where is ASN Kidney Week 2026 held?

ASN Kidney Week 2026 will take place in Denver, CO, from October 21-25.

What does the SPARTAN analysis focus on?

The final SPARTAN analysis provides insights into the potential of FILSPARI® in treatment.

ShareAdd on Google
Tags: TVTX Travere Therapeutics FILSPARI IgA nephropathy FSGS ASN Kidney Week
Last updated: Oct 2, 2026

Biotech snapshot

Cash runway
$489M liquidity · $0M/mo burn
Low dilution risk
Lead asset
SparsentanPhase 2
ANCA Associated Vasculitis →

Catalyst track record

+68%
best trade around TVTX's most recent catalyst

Peak hindsight return over a 120-day window, across 10 tracked FDA/PDUFA catalysts for TVTX.

See every catalyst's timing & PoA →